Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

(2013) S. F. Dent et al.   INVESTIGATIONAL NEW DRUGS

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

(2013) Carlos Graux et al.   LEUKEMIA RESEARCH

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

(2012) Hielke J. Meulenbeld et al.   BJU INTERNATIONAL

Danusertib, an aurora kinase inhibitor

(2012) Hielke J Meulenbeld et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors

(2012) Gary K. Schwartz et al.   INVESTIGATIONAL NEW DRUGS

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

(2012) F J Giles et al.   LEUKEMIA

Aurora kinase inhibitors as anti-cancer therapy

(2010) Warren Lok et al.   ANTI-CANCER DRUGS

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

(2009) Neeltje Steeghs et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER